Iovance Biotherapeutics (IOVA) Scheduled to Post Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Iovance Biotherapeutics to post earnings of ($0.45) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.01). The business had revenue of $0.48 million during the quarter, compared to analysts' expectations of $1.44 million. During the same quarter last year, the firm posted ($0.64) earnings per share. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Up 3.0 %

Shares of IOVA stock traded up $0.38 during trading hours on Thursday, hitting $12.88. 4,087,231 shares of the company were exchanged, compared to its average volume of 8,236,546. The firm has a fifty day moving average of $14.01 and a 200 day moving average of $9.40. Iovance Biotherapeutics has a 1 year low of $3.21 and a 1 year high of $18.33. The firm has a market cap of $3.60 billion, a PE ratio of -6.85 and a beta of 0.66.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 29th. Piper Sandler raised their price target on shares of Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an "overweight" rating in a report on Thursday, March 14th. Chardan Capital boosted their price objective on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research note on Tuesday, February 20th. StockNews.com raised shares of Iovance Biotherapeutics to a "sell" rating in a research note on Friday, February 2nd. Finally, JMP Securities upped their price target on shares of Iovance Biotherapeutics from $18.00 to $25.00 and gave the stock a "market outperform" rating in a research report on Tuesday, February 20th. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $24.64.

Insider Activity at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $9.15 per share, with a total value of $2,287,500.00. Following the transaction, the director now directly owns 320,150 shares in the company, valued at approximately $2,929,372.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.40% of the stock is currently owned by company insiders.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.